The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Rydapt (midostaurin) as the first treatment for rare blood disorder. It has been recommended as
Abecma has been approved to treat adult relapsed and refractory multiple myeloma patients who have received a minimum of three prior therapies and have experienced disease progression on
CM Life Sciences II and SomaLogic have collaborated with Twist Bioscience to discover novel therapeutic targets and antibodies. The partnership aims to develop antibodies and discover drugs based
The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly and Company’s Jardiance (empagliflozin) to treat Heart Failure with reduced Ejection Fraction (HFrEF). Jardiance
Aurinia Pharmaceuticals has bought two new pipeline assets to boost its rare autoimmune and kidney-related disease portfolio. These pipeline assets are AUR200 and AUR300 Aurinia paid an upfront
Gritstone bio and the Coalition for Epidemic Preparedness Innovations (CEPI) have signed a funding agreement to advance the development of the former’s second-generation Covid-19 vaccine programme (CORAL) against
Pfizer and its partner BioNTech have submitted the initial data of an early-stage trial to the US Food and Drug Administration (FDA) to support the authorisation of a
Merck, called MSD outside the US and Canada, has initiated a rolling submission to Health Canada for molnupiravir, an investigational oral antiviral therapy for the treatment of Covid-19.
Moderna has announced that in a new study its Covid-19 messenger ribonucleic acid (mRNA) vaccine showed durable efficacy in generating neutralising antibodies against SARS-CoV-2 variants of concern. The
The US Food and Drug Administration (FDA) has authorised additional doses of Pfizer-BioNTech and Moderna Covid-19 vaccines for certain people with compromised immune systems. The regulatory agency has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.